inclusion criteria: 1. male and female adults age (≥19 years at the time of informed consent) 2. body weight (≥ 45 kg at screening) 3. participants must be confirmed as having covid-19 using real-time reverse transcription polymerase chain reaction (rt-pcr) test and specimens collected from upper airway (nasopharyngeal specimen) within 96 hours prior to randomization. 4. females must be non-pregnant and non-lactating, and must use an acceptable, highly effective double contraception from screening until study completion, including the follow-up period. males must be surgically sterile (\>30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a woman of childbearing potential (wocbp), the participant and his partner must be surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method from screening until study completion, including the follow-up period. * hormonal contraception (with approved oral contraceptives, long-acting implantable hormones, injectable hormones), intra uterine device, condoms , sterilization (vasectomy, tubal occlusion, etc.)

inclusion criteria: 1. male and female adults age (≥19 years at the time of informed consent) 2. body weight (≥ 45 kg at screening) 3. participants must be confirmed as having covid-19 using real-time reverse transcription polymerase chain reaction (rt-pcr) test and specimens collected from upper airway (nasopharyngeal specimen) within 96 hours prior to randomization. 4. females must be non-pregnant and non-lactating, and must use an acceptable, highly effective double contraception from screening until study completion, including the follow-up period. males must be surgically sterile (\>30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a woman of childbearing potential (wocbp), the participant and his partner must be surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method from screening until study completion, including the follow-up period. * hormonal contraception (with approved oral contraceptives, long-acting implantable hormones, injectable hormones), intra uterine device, condoms , sterilization (vasectomy, tubal occlusion, etc.)

inclusion criteria: male and female adults age (≥19 years at the time of informed consent) body weight (≥ 45 kg at screening) participants must be confirmed as having covid-19 using real-time reverse transcription polymerase chain reaction (rt-pcr) test and specimens collected from upper airway (nasopharyngeal specimen) within 96 hours prior to randomization. females must be non-pregnant and non-lactating, and must use an acceptable, highly effective double contraception from screening until study completion, including the follow-up period. males must be surgically sterile (>30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a woman of childbearing potential (wocbp), the participant and his partner must be surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method from screening until study completion, including the follow-up period. hormonal contraception (with approved oral contraceptives, long-acting implantable hormones, injectable hormones), intra uterine device, condoms , sterilization (vasectomy, tubal occlusion, etc.)

inclusion criteria: male and female adults age (≥19 years at the time of informed consent) body weight (≥ 45 kg at screening) participants must be confirmed as having covid-19 using real-time reverse transcription polymerase chain reaction (rt-pcr) test and specimens collected from upper airway (nasopharyngeal specimen) within 96 hours prior to randomization. females must be non-pregnant and non-lactating, and must use an acceptable, highly effective double contraception from screening until study completion, including the follow-up period. males must be surgically sterile (>30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a woman of childbearing potential (wocbp), the participant and his partner must be surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method from screening until study completion, including the follow-up period. hormonal contraception (with approved oral contraceptives, long-acting implantable hormones, injectable hormones), intra uterine device, condoms , sterilization (vasectomy, tubal occlusion, etc.)

inclusion criteria: 1. male and female adults age (≥19 years at the time of informed consent) 2. body weight (≥ 45 kg at screening) 3. participants must be confirmed as having covid-19 using real-time reverse transcription polymerase chain reaction (rt-pcr) test and specimens collected from upper airway (nasopharyngeal specimen) within 96 hours prior to randomization. 4. females must be non-pregnant and non-lactating, and must use an acceptable, highly effective double contraception from screening until study completion, including the follow-up period. males must be surgically sterile (>30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a woman of childbearing potential (wocbp), the participant and his partner must be surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method from screening until study completion, including the follow-up period. - hormonal contraception (with approved oral contraceptives, long-acting implantable hormones, injectable hormones), intra uterine device, condoms , sterilization (vasectomy, tubal occlusion, etc.)

inclusion criteria: 1. male and female adults age (≥19 years at the time of informed consent) 2. body weight (≥ 45 kg at screening) 3. participants must be confirmed as having covid-19 using real-time reverse transcription polymerase chain reaction (rt-pcr) test and specimens collected from upper airway (nasopharyngeal specimen) within 96 hours prior to randomization. 4. females must be non-pregnant and non-lactating, and must use an acceptable, highly effective double contraception from screening until study completion, including the follow-up period. males must be surgically sterile (>30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a woman of childbearing potential (wocbp), the participant and his partner must be surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method from screening until study completion, including the follow-up period. - hormonal contraception (with approved oral contraceptives, long-acting implantable hormones, injectable hormones), intra uterine device, condoms , sterilization (vasectomy, tubal occlusion, etc.)

inclusion criteria: 1. male and female adults age (≥19 years at the time of informed consent) 2. body weight (≥ 45 kg at screening) 3. participants must be confirmed as having covid-19 using real-time reverse transcription polymerase chain reaction (rt-pcr) test and specimens collected from upper airway (nasopharyngeal specimen) within 72 hours prior to randomization. 4. females must be non-pregnant and non-lactating, and must use an acceptable, highly effective double contraception from screening until study completion, including the follow-up period. males must be surgically sterile (>30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a woman of childbearing potential (wocbp), the participant and his partner must be surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method from screening until study completion, including the follow-up period. - hormonal contraception (with approved oral contraceptives, long-acting implantable hormones, injectable hormones), intra uterine device, condoms , sterilization (vasectomy, tubal occlusion, etc.)

inclusion criteria: 1. male and female adults age (≥19 years at the time of informed consent) 2. body weight (≥ 45 kg at screening) 3. participants must be confirmed as having covid-19 using real-time reverse transcription polymerase chain reaction (rt-pcr) test and specimens collected from upper airway (nasopharyngeal specimen) within 72 hours prior to randomization. 4. females must be non-pregnant and non-lactating, and must use an acceptable, highly effective double contraception from screening until study completion, including the follow-up period. males must be surgically sterile (>30 days since vasectomy with no viable sperm), abstinent, or if engaged in sexual relations with a woman of childbearing potential (wocbp), the participant and his partner must be surgically sterile (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or using an acceptable, highly effective contraceptive method from screening until study completion, including the follow-up period. - hormonal contraception (with approved oral contraceptives, long-acting implantable hormones, injectable hormones), intra uterine device, condoms , sterilization (vasectomy, tubal occlusion, etc.)